Help MAPS Make Pharmaceutical MDMA

Visit our Team Page to start your own Fundraising Page!

Watch the free video of the MAPS 30th Anniversary Banquet and Celebration from April 17, 2016.

All contributions will help fund the purchase of one kilogram of MDMA manufactured under current Good Manufacturing Practices (GMP) to be used in upcoming Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).

We're asking you—the worldwide community of people wanting to make psychedelic therapy a legal treatment—to donate and engage your network to help raise $400,000 for the MDMA supply for Phase 3 trials. Additional funds raised will go towards research to make MDMA-assisted psychotherapy a U.S. Food and Drug Administration (FDA)-approved treatment for PTSD.

Register to Host a Global Psychedelic Dinner

You can also send your gift directly to MAPS by making your check out to MAPS and mailing it to:

MAPS Dinners
1115 Mission Street
Santa Cruz, CA, 95060 USA

How will your gift help?

Every dollar you give will help make psychedelic therapy a legal treatment by paying for the manufacture of 1 kilogram of pharmaceutical-grade MDMA, helping us complete the clinical trials necessary to make MDMA-assisted psychotherapy a legal prescription treatment for PTSD. All donations are tax-deductible.

What is MAPS?

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Since 1986, MAPS has disbursed over $26 million to scientific research and public education about the risks and benefits of psychedelics and marijuana. This April, we're asking you to join us in celebrating our 30 years of pioneering research and honest education through the Global Psychedelic Dinners and 30th Anniversary Banquet and Celebration in Oakland, Calif. Almost all our support comes from individuals and family foundations.

MAPS has completed an international series of Phase 2 clinical trials of MDMA-assisted psychotherapy for PTSD, and is now preparing for the much larger Phase 3 trials required to obtain U.S. Food and Drug Administration (FDA) approval, starting in 2017. As long as we receive the necessary funding, we anticipate FDA approval for MDMA-assisted psychotherapy for PTSD by 2021.